spacer
home > epc > Winter 2010
PUBLICATIONS

European Pharmaceutical Contractor

epc
Winter 2010
   
Text
PDF
bullet
Marketplace & Business

Tactics and Strategies

The pharmaceutical industry continues to consolidate with many companies looking to lower their costs. Andrew Kelley of Patheon identifies the benefits of seeking partnerships with suppliers when outsourcing, rather than opting for a transactional relationship.

 
view
download pdf

Why Provide Early Market Access?

Who should get early access to medicines and how do we balance patients’ needs with safety concerns? Simon Estcourt of Idis poses some key questions to consider in a discussion on using named patient programmes to provide early access to medicines for patients who most need them.

 
view
download pdf

The Science of Alliance

Brenda Hoeper and Cathy Thompson at i3 Statprobe explore the current marketplace conditions as well as the elements necessary for successful alliances, illustrating this with a case study.

 
view
download pdf

Medical Writing: Outsourcing Guide

Julia Forjanic Klapproth of Trilogy Writing & Consulting highlights the four main stages of outsourcing medical writing, the questions to ask when selecting a company, and how regular communication can save both money and time in the clinical development programme.

 
view
download pdf

Towards Greater Certainty

As regulators, providers and payers demand more evidence of product performance in the real world, a new generation of service providers are emerging in the biopharmaceutical industry, as Ethan D Leder at United BioSource Corporation explains.

 
view
download pdf

The CRO Scene in 2010

EPC’s editor, Graham Hughes, reviews the performance of CROs in 2010, looking at outsourcing trends, the current R&D pipelines and measures to address declining productivity.

 
view
download pdf
bullet
SITE SELECTION

Putting Kazakhstan on the Clinical Trials Map

Like any other territory at the beginning of its clinical trial career, Kazakhstan has its strengths and weaknesses. Anna Ravdel and Irina Kim of Synergy Research Group make a case for this CIS state as a new destination for clinical research.

 
view
download pdf

Research in India: Tomorrow and Beyond

India has been a popular destination for clinical trials and, as there is an increasing acceptance of Indian data, Viraj Rajadhyaksha stresses that there is a need to ensure science and operational excellence remain top priorities.

 
view
download pdf
bullet
Paediatrics Special Focus: Clinical Development and Regulatory Updates

In Search of Safe and Effective Medicines

Paolo Tomasi at the European Medicines Agency points out that, despite the controversy that still remains regarding the use of children as subjects of scientific studies, significant regulatory changes can make research safer and lead to wider availability of medicines for children.

 
view
download pdf

Paediatric Pioneers

The challenges of developing drugs for rare diseases are well recognised but as pertinent as ever; Karen Aiach of Alliance SANFILIPPO highlights recent progress for Sanfilippo syndrome – an orphan disease affecting only one in 700,000 children.

 
view
download pdf

PIP: Lab Perspectives

Both regulatory authorities and pharmaceutical manufacturers agree on the need for running paediatric studies to reduce the ‘off-label use’ of drugs in children. Katja Neuer-Etscheidt and Hermann Schulz at INTERLAB discuss how using a centralised laboratory can help to streamline this process.

 
view
download pdf
bullet
DRUG DISCOVERY, DELIVERY & THERAPEUTICS

Diabetes: Making Strategic Partnerships

Rickey Reinhardt of Covance explains the need for pharma and biotech companies to partner with CROs to develop an integrated drug development strategy as a way of bringing more efficient combination therapies with better side effect profiles to market.

 
view
download pdf

In Search of Innovation

TQT trials are now required in the regulatory process in many countries, according to the ICH’s E14 guidance. Alan Copa of Cetero Research reveals some approaches that can be used to improve the accuracy of TQT trial data, while keeping costs under control.

 
view
download pdf

In the Heart of Russia

In 2009, cardiology represented the fourth largest area of clinical research in Russia and the region ranked 11th internationally in terms of pharmaceutical sales. Lyubov Semenova at Pharm-Olam makes a case for Russia as a leader in global cardiology research.

 
view
download pdf
bullet
Data Management & IT Solutions

Flexible LIMS

The implementation of a modern clinical trial LIMS provides many benefits to the clinical development process by allowing quick identification and resolution of queries which helps to increase the value for trial sponsors, reveals Edward Krasovec at STARLIMS.

 
view
download pdf

The Age of EDC

Gregor Spiekermann of Merz Pharmaceuticals GmbH looks at how electronic data capture has progressed over the last 10 years, reviewing today’s challenges and the role that EDC provider partnerships can play.

 
view
download pdf

Integrated Science

LIMS, ELN and SDMS: they play different roles but are they all needed in the lab? Robert Pavlis at Labtronics suggests that real-time integration between these applications is what is most important, and introduces a fourth system – the iLAB, or integrated lab – as the solution.

 
view
download pdf
bullet
Cool Chain, Labs & Logistics

A Warmer Reception

Omoshile Clement, Rolf Müller and Judy Müller-Cohn at Biomatrica Inc reveal how ambient temperature-based nucleic acid storage and shipping can potentially offer significant savings compared to current cold-freezing methods.

 
view
download pdf

Securing the Supply Chain

According to the WHO, 25 per cent of all vaccine products arrive at their final destination in a degraded state. Rüdiger Lomb of World Courier recommends that pharmaceutical practitioners select their supply chain service providers with care.

 
view
download pdf
   
spacer



Published quarterly in
February, May,
August, and November

News and Press Releases

Sphere Fluidics hires 10 new UK and US staff in its plan to scale internationally

Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites. Rob Treanor and Andrew Campbell join Sphere Fluidics as Director of Operations and Director of Finance, respectively alongside new hires to its sales, operations and scientific teams. These appointments will expand the Company’s commercial capabilities and facilitate service and support for new and existing Cyto-Mine® customers in both the UK and US.
More info >>

White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement